CLAIM CARD
The evidence synthesis for dosing and pharmacokinetics draws on a single network meta-analysis examining agent-specific safety signals of SGLT2 inhibitors and GLP-1 receptor agonists in the gastrointestinal domain. The analysis evaluated multiple agents across the combined trial population, with the primary outcome being the incidence of intestinal obstruction reported across the included randomized controlled trials. This pharmacovigilance-oriented synthesis provides dose- and agent-stratified safety data that informs the risk-benefit calculus for clinical deployment of these glucose-lowering agents.
Evidence grade: exploratory
Contradiction status: none
Publication: f0b4aa8b-f260-4fc6-8419-dac0b0a34715
Provenance: Derivation Web chain
Citation Support
source_1Movila 2026source_2Borges 2024source_3Jansz 2026source_4Ali 2026source_5Cersosimo 2025